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Introduction
Macrophages are critical effector cells of  the innate immune system. Multiple groups, including our own, 
have reported that macrophages from aged mice demonstrate a functional drift compared with those isolated 
from young mice. For example, aged macrophages exhibit epigenomic changes, leading to reduced autophag-
ic capacity (1), and are defective in their ability to fight viral infections due to reduced phagocytic activity (2). 
Moreover, aged macrophages are skewed toward a proangiogenic gene and cytokine expression profile, which 
leads to dysregulated inflammation and the inability to inhibit pathological angiogenesis (3). Aged macro-
phages also exhibit impaired cholesterol efflux due to decreased Abca1 expression, leading to intracellular 
cholesterol accumulation and pathologic vascular proliferation (4). Age-associated macrophage dysfunction 
has been proposed to contribute to the pathogenesis of  numerous diseases of  aging, including age-related 
macular degeneration (AMD) and atherosclerosis (5). In addition, age-associated changes in microglia, the 
major resident immune cell in the retina with similar phagocytic functions, may also promote AMD (6).
AMD is a leading cause of  blindness in industrialized nations (7) and displays a complex disease 
course characterized, initially, by accumulation of  cholesterol-rich deposits known as drusen underneath 
the retina (5, 8). Though drusen themselves do not typically cause vision loss, they are risk factors for 
progression to one of  2 forms of  advanced AMD: advanced neovascular (wet) AMD, characterized by 
pathologic subretinal angiogenesis, or advanced dry AMD, characterized by geographic atrophy second-
ary to loss of  retinal neurons and underlying cells. Both forms of  advanced AMD can cause debilitating 
blindness, though wet AMD causes a significant portion of  the vision loss associated with AMD (9). While 
anti-VEGF therapies have revolutionized treatment options for wet AMD, an important subset of  patients 
is un- or underresponsive to this therapy (8). Of  interest, genome-wide association studies show that poly-
morphisms in lipid-related genes, including hepatic lipase (LIPC), ATP-binding cassette transporter mem-
ber 1 (ABCA1), and cholesterol ester transfer protein (CETP), are associated with advanced AMD (10), 
supporting the idea that impaired cholesterol homeostasis contributes to AMD pathogenesis.
Macrophage aging is pathogenic in diseases of the elderly, including age-related macular 
degeneration (AMD), a leading cause of blindness in older adults. However, the role of microRNAs, 
which modulate immune processes, in regulating macrophage dysfunction and thereby promoting 
age-associated diseases is underexplored. Here, we report that microRNA-150 (miR-150) 
coordinates transcriptomic changes in aged murine macrophages, especially those associated with 
aberrant lipid trafficking and metabolism in AMD pathogenesis. Molecular profiling confirmed 
that aged murine macrophages exhibit dysregulated ceramide and phospholipid profiles compared 
with young macrophages. Of translational relevance, upregulation of miR-150 in human peripheral 
blood mononuclear cells was also significantly associated with increased odds of AMD, even after 
controlling for age. Mechanistically, miR-150 directly targets stearoyl-CoA desaturase-2, which 
coordinates macrophage-mediated inflammation and pathologic angiogenesis, as seen in AMD, in 
a VEGF-independent manner. Together, our results implicate miR-150 as pathogenic in AMD and 
provide potentially novel molecular insights into diseases of aging.
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Impaired cholesterol homeostasis also contributes to the pathogenesis of  atherosclerosis. Atheroscle-
rotic plaque formation begins when circulating monocytes adhere to the vascular endothelium, migrate to 
the sub-endothelial space, and activate into macrophages that take up lipids and become foam cells (11, 
12). Past studies have demonstrated that the activation/polarization state of  macrophages is important for 
predicting plaque phenotype and stability (13, 14). For example, in patients with hypercholesterolemia, 
macrophages polarize to a more proinflammatory state, which could predispose to plaque formation (15). 
Moreover, macrophage cholesterol efflux capacity in human patients is a clinically relevant predictor of  
atherosclerotic coronary artery disease (16), suggesting that perturbations in cholesterol homeostasis pro-
mote disease. Remarkably, atherosclerotic plaques and drusen have similar lipid compositions (17–20), uni-
fying the pathogenic pathways underlying these diseases. Based on these similarities, some have proposed 
that it may be possible to repurpose statins, lipid-lowering drugs used to treat atherosclerosis, for treating 
AMD (21, 22), although not all studies have yielded these same conclusions (23).
Despite these advances in our understanding of  the phenotype of  aged macrophages and how such 
changes contribute to age-associated diseases, the molecular mechanisms by which macrophages drift 
toward the disease-promoting phenotype remain elusive. Given the immense spectrum of  these changes 
in aged macrophages, we hypothesized that microRNAs (miRs) may regulate the transcriptome of  macro-
phages and, thereby, the transition of  macrophages to a disease-promoting phenotype. The ability of  miRs 
to target multiple genes makes them strong candidates as molecular regulators that skew macrophages 
toward a disease-promoting phenotype. Previous studies have examined the miR signatures of  AMD by 
profiling eye fluids, such as human vitreous humor and plasma, providing phenotypic characterization, but 
they have failed to provide mechanistic insights into the underlying disease etiology (24, 25). Therefore, 
further elucidation of  the target genes of  these miRs, the affected cell types, and the molecular pathways 
involved is necessary for a more complete understanding of  disease pathogenesis.
In this study, we sought to identify one or more miRs that regulate the disease-promoting programmat-
ic changes in macrophages that are associated with AMD. Our results demonstrate that miR-150 is highly 
upregulated both in disease-promoting murine macrophages and in human peripheral blood mononuclear cells 
(PBMCs) from AMD patients. Moreover, we show that miR-150 regulates macrophage-mediated inflammation 
and pathologic angiogenesis independently from VEGF by targeting stearoyl-CoA desaturase-2 (Scd2), suggest-
ing that it regulates the transition of macrophages from a healthy profile to the AMD-promoting phenotype. Ulti-
mately, these findings provide insight into the mechanisms underlying the pathological programmatic changes 
in aged macrophages and may lead to the identification of novel therapeutic targets and candidate biomarkers.
Results
Aged macrophages have distinct cholesterol-responsive miR networks. Since miRs can regulate numerous target 
genes, we hypothesized that miRs may globally regulate the macrophage’s response to exogenous cholester-
ol. We first sought to identify cholesterol-responsive miRs by performing a microarray, comparing untreat-
ed macrophages versus macrophages treated with acetylated LDL (acLDL) or oxidized LDL (oxLDL). We 
previously showed that aged and young macrophages handle cholesterol differently and that aged macro-
phages demonstrate altered capacity to metabolize cholesterol (4). As such, we profiled aged and young 
macrophages separately to accurately capture the response of  these cells to exogenous cholesterol. In young 
macrophages, 10 miRs were similarly downregulated in response to both acLDL and oxLDL (Figure 1A). 
In contrast, in aged macrophages, 5 miRs were similarly dysregulated in response to both acLDL and 
oxLDL: 3 downregulated and 2 upregulated (Figure 1B). These findings suggest that, in macrophages, 
miRs are altered after exposure to cholesterol and may indeed orchestrate the macrophage’s response to 
cholesterol. Furthermore, these findings suggest that the distinct miR responses in aged versus young mac-
rophages may underlie their distinct responses to exogenous cholesterol.
In addition to these cholesterol-responsive miRs, we hypothesized that there may be a separate net-
work of  miRs that regulate the broad spectrum of  differences between disease-promoting, aged macro-
phages and young macrophages. Such a miR must not only demonstrate altered expression with aging, 
but must also have consistent dysregulation regardless of  treatment with cholesterol. Five miRs were 
upregulated in aged macrophages and maintained the same pattern of  dysregulation in aged versus 
young macrophages after treatment with acLDL or oxLDL (Figure 1C). miR-150 was the strongest 
candidate for further study, given that it had the highest fold change in aged versus young macrophages 
and since the others did not validate after further characterization.
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miR-150 is upregulated in aged macrophages of  diverse origins. To validate the microarray data, we 
performed quantitative PCR (qPCR) with independent samples. Indeed, aged peritoneal macrophages 
(PMs) had 9-fold increased miR-150 expression at baseline compared with young PMs (Figure 1D). 
To determine whether this phenomenon was lineage specific, we also measured miR-150 expression 
in splenic macrophages (SMs) and BM-derived macrophages (BMDMs). Similar to PMs, we found 
that aged SMs (Figure 1E) and BMDMs (Figure 1F) exhibited 3-fold higher expression of  miR-150 at 
baseline compared with young SMs and BMDMs. Next, we sought to confirm that miR-150 upregu-
lation in aged macrophages is unaffected by exposure to exogenous cholesterol or LPS. Indeed, aged 
PMs treated with acLDL, oxLDL, or LPS exhibited higher miR-150 expression than similarly treated 
young PMs (Figure 1G). Likewise, oxLDL- and LPS-treated aged BMDMs also had higher miR-150 
expression compared with similarly treated young BMDMs (Figure 1H). Cumulatively, these find-
ings provide strong evidence that miR-150 upregulation may indeed skew macrophages toward the 
disease-promoting, aged phenotype.
Figure 1. microRNA-150 is upregulated in aged macrophages of diverse origins. (A) In young macrophages, 10 microRNAs were downregulated similarly in 
response to acetylated low-density lipoprotein (acLDL) and oxidized low-density lipoprotein (oxLDL). (B) In aged macrophages, 5 microRNAs were dysregu-
lated similarly in response to acLDL and oxLDL. (C) In untreated (UT), acLDL-treated, and oxLDL-treated macrophages, 5 microRNAs were dysregulated simi-
larly in aged and young macrophages under the same treatment conditions. microRNA-150 was upregulated in aged peritoneal macrophages (PM) (D; n = 12/
group; 2-tailed Mann-Whitney U test), aged splenic macrophages (SM) (E; n = 13/group; 2-tailed Mann-Whitney U test), and aged BM-derived macrophages 
(BMDM) (F; n = 10/group; 2-tailed, unpaired Welch’s t test). (G) Upregulation of microRNA-150 in aged PMs was not affected by treatment with acLDL (n 
= 7/group; 2-tailed Mann-Whitney U test), oxLDL (n = 7/group; 2-tailed, unpaired Welch’s t test), or LPS (n = 5/group; 2-tailed Mann-Whitney U test). (H) 
Upregulation of microRNA-150 in aged BMDMs was not affected by treatment with oxLDL (n = 5/group; 2-tailed Mann-Whitney U test) or LPS (n = 5/group; 
2-tailed Mann-Whitney U test). Open circles depict individual data points; graphs depict mean ± SEM (A–F) (*P < 0.05; **P < 0.01; ****P < 0.0001).
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miR-150 overexpression reprograms the macrophage transcriptome. We next sought to determine the mecha-
nism by which miR-150 skews macrophages toward the aged phenotype. To elucidate the cellular processes 
and pathways regulated by miR-150, we performed RNA sequencing (RNA-Seq) to identify the transcrip-
tomic networks dysregulated under conditions of  miR-150 overexpression, comparing young macrophages 
transfected with miR-150–overexpressing mimic (miR-150OE) to young macrophages transfected with a 
nontargeting negative control (NC) mimic. From RNA-Seq, we obtained an average of  35,607,314 reads 
per sample (n = 11), and of  these, an average of  32,535,035 reads (91.4%) mapped to the mouse genome 
(Mus_musculus reference build Ensembl_R76). We performed hierarchical clustering, revealing clear dif-
ferences between the transcriptomes of  miR-150OE and NC-transfected PMs (Figure 2A).
Figure 2. microRNA-150 (miR-150) regulates inflammation and lipid metabolism in macrophages. (A) RNA-sequencing followed by hierarchi-
cal clustering revealed clear transcriptomic differences between macrophages transfected with miR-150 mimic versus those transfected with a 
nontargeting negative control. Pathway analysis of the dysregulated genes in miR-150–overexpressing macrophages that are also dysregulated in 
aged macrophages (Jonathan B. Lin, unpublished observations) suggested perturbations in numerous gene ontology (GO) processes (B), process 
networks (C), and pathway maps (D). The altered transcriptomic profile of miR-150–overexpressing macrophages suggested dysregulation of 
numerous inflammation and immune response process networks (C; brown and purple, respectively) and aberrant lipid trafficking and metabolism 
in age-related macular degeneration (D; purple).
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Figure 3. Aged macrophages have altered ceramide and phospholipid profiles. (A) Aged macrophages contained significantly more long-chain C16:0 than 
young macrophages but similar levels of very long-chain C22:0 and C24:0 (n = 5/group; 2-tailed, unpaired Welch’s t test), resulting in decreased C22:0/
C16:0 and C24:0/C16:0 ratios (B; n = 5/group; 2-tailed, unpaired Welch’s t test). Young and aged macrophages had similar phosphatidylglycerol-D16:0-18:1 
(PG-D16:0-18:1) content (C; n = 5/group; 2-tailed, unpaired student’s t test). Aged macrophages had higher total phosphatidylcholine (PC) (D; n = 5/group; 
2-tailed, unpaired student’s t test) and higher total phosphatidylethanolamine (PE) (E; n = 5/group; 2-tailed, unpaired student’s t test), but they had 
similar total phosphatidylinositol (PI) (F; n = 5/group; 2-tailed, unpaired Welch’s t test) and similar total phosphatidylserine (PS) (G; n = 5/group; 2-tailed, 
unpaired Welch’s t test). Analysis of individual species revealed an interaction between age and species identity with increased levels of certain species 
but not others within each phospholipid class (H–K; n = 5/group; 2-way, repeated-measures ANOVA with Bonferroni post-hoc test). Open circles depict 
individual data points; graphs depict mean ± SEM (A–G) (*P < 0.05; **P < 0.01; #P < 0.0001).
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To determine the subset of  these miR-150–regulated genes that are also dysregulated in aged mac-
rophages, we overlaid the RNA-Seq results onto the results of  a previous microarray that we performed 
comparing aged versus young macrophages (Jonathan B. Lin, unpublished observations). The intersection 
between these gene lists identifies genes dysregulated in aged murine macrophages that may be regulated by 
miR-150 upregulation. We identified 160 commonly dysregulated genes with a |fold change| > 1.2 both 
in miR-150OE versus NC-transfected macrophages and in aged versus young macrophages. To determine 
whether these genes suggested abnormalities in specific pathways, which may provide insight into the mech-
anism by which miR-150 upregulation promotes age-associated disease, we performed pathway analysis 
with MetaCore for enrichment by gene ontology (GO) processes, process networks, and pathway maps 
(Figure 2, B–D). Numerous diverse GO processes were enriched for, indicating that miR-150 regulates broad 
cellular pathways in macrophages (Figure 2B). Of interest, inflammation and immune response process 
networks were 5 of  the 9 most enriched process networks (Figure 2C). These findings confirm that there is 
immune dysregulation in aged macrophages associated with miR-150 upregulation. Remarkably, aberrant 
lipid trafficking and metabolism in AMD was the third most enriched pathway map (Figure 2D), validating 
our hypothesis that miR-150 regulates the transition of  macrophages to the AMD-promoting phenotype.
Disease-promoting macrophages have altered phospholipid and ceramide profiles. In AMD, the interaction 
between dysregulated macrophage cholesterol homeostasis and aging is implicated in the pathophysiology 
of  disease. To better understand this relationship, we performed lipidomics to determine whether aged 
macrophages have altered lipid profiles as possible consequences of  aberrant lipid trafficking and metabo-
lism. We focused on components of  the plasma membrane, including ceramides and phospholipids, since 
the composition and organization of  the plasma membrane have been shown to regulate macrophage func-
tion (26). Aged macrophages contained significantly more long-chain ceramide (C16:0) than young mac-
rophages but similar levels of  very long–chain C22:0 and C24:0 (Figure 3A). Consistent with increased 
C16:0, we observed a significant decrease in both the C22:0/C16:0 and C24:0/C16:0 ratios in aged versus 
young macrophages (Figure 3B). These findings indicate that aged macrophages exhibit remodeling of  
their ceramide composition from very long–chain to long-chain species.
In the phosphatidylglycerol (PG) class, PG-D16:0-18:1 was the only detectable species, and there 
was no significant difference in content between aged and young macrophages (Figure 3C). However, 
numerous individual species were detected for each of  the other phospholipid classes. Overall, aged mac-
rophages contained more total phosphatidylcholine (PC; Figure 3D) and more total phosphatidyletha-
nolamine (PE; Figure 3E) than young macrophages but similar total phosphatidylinositol (PI; Figure 3F) 
and similar total phosphatidylserine (PS; Figure 3G). Further analysis of  the individual species within 
each phospholipid class by 2-way, repeated-measures ANOVA revealed a significant interaction between 
the main effects of  species identity and age for all 4 phospholipid classes (Figure 3, H–K), indicating 
that the increased total PC and total PE in aged macrophages were driven by increases in specific species 
within these phospholipid classes. Post hoc testing showed that the significantly increased species were 
generally phospholipids containing fatty acids with multiple double bonds, suggesting a shift toward 
unsaturated fatty acids (Figure 3, H–K). Based on these findings, we propose that aberrant lipid traffick-
ing and metabolism in aged macrophages leads to this disruption in ceramide and phospholipid profiles, 
which may contribute to macrophage dysfunction in age-associated diseases.
Table 1. Demographic and clinical characteristics of human subjects
Variable Control AMD P value
Age, mean (SD)  64.57 (10.27) 75.48 (12.77) <0.001A
Sex, n
Male 36 20 0.282B
Female 27 23
AMD status, n
No AMD 63 0 N/A
Early AMD 0 20
Advanced neovascular (wet) AMD 0 23
ASignificant by 2-tailed, unpaired Welch’s t test; BNonsignificant by χ2 test.
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miR-150 upregulation is associated with AMD in humans. To assess the translational relevance of these find-
ings, we recruited human patients with early AMD or advanced neovascular (wet) AMD and non-AMD 
controls in a case-control study design. Demographic and clinical information of the participants are shown 
in Table 1. From these patients, we collected PBMCs, which contain mostly monocytes, and quantified 
miR-150 copy number in these samples. On average, AMD patients had significantly higher PBMC miR-150 
levels compared with control subjects (Figure 4A). When we subdivided AMD patients into early AMD and 
wet AMD groups, we observed higher PBMC miR-150 levels in early AMD patients compared with controls 
and in wet AMD patients compared with controls (Figure 4B). There was, however, no significant difference in 
PBMC miR-150 levels between early and wet AMD patients (Figure 4B). These findings suggest that increased 
PBMC miR-150 levels are associated with developing AMD but not with disease progression. We next sought 
to determine whether age affected PBMC miR-150 levels, since AMD patients tended to be older than non-
AMD controls (Table 1). We found that there was no significant correlation between age and PBMC miR-150 
levels in AMD patients (rs = 0.1596, P = 0.3066) or in control subjects (rs = –0.2002, P = 0.1157) (Figure 4C), 
suggesting that there is no significant association between PBMC miR-150 levels and age.
To model the relationship between PBMC miR-150 levels and AMD status and to rigorously control for a 
possible — albeit unlikely — effect of age, we generated a binary logistic regression model with the predictor 
variables of age, sex, and log10-transformed PBMC miR-150 levels and the outcome of AMD. The overall model 
was statistically significant (LR χ2  = 47.4, degrees of freedom [df] = 3, P < 0.001) and had good fit (χ2 = 9.4, df  
= 8, P = 0.311). As expected, age was a significant predictor of AMD (P < 0.001) with a β coefficient of 0.082, 
indicating that each additional year of age was associated with increased odds of having AMD (adjusted odds 
ratio [aOR] = 1.086; 95% CI, 1.04–1.13). Of significant interest, even after controlling for the effects of age and 
sex on miR-150 levels, log10-transformed PBMC miR-150 levels were highly associated with AMD (P < 0.001) 
with a β coefficient of 3.367, indicating that each additional 10-fold increase in PBMC miR-150 levels was asso-
ciated with 29.0-fold increased odds of having AMD (95% CI, 5.9–141.5). To determine the efficacy of PBMC 
miR-150 levels as a potential marker of AMD, we generated a receiver operating characteristic (ROC) curve 
and found that the area under the ROC curve was 0.860 (95% CI, 0.788–0.933), indicating good discrimination.
Furthermore, we performed conjunctive analysis to illustrate the relationship between PBMC miR-150 
levels, age, and the outcome of  AMD. We divided patients into tertiles by PBMC miR-150 levels (cutoffs 
of  4.5 × 106 and 9.5 × 106 copies/ng RNA) and by age (i.e., above versus below a median of  67.47 years), 
tabulating the AMD prevalence in each conjoined cell (Table 2). This analysis demonstrated a clear step-
wise increase in prevalence of  AMD going from the lowest to the highest tertile of  PBMC miR-150 levels in 
participants both above median age (i.e., from 18.8% to 53.8% to 87.5%) and below median age (i.e., from 
15.8% to 17.4% to 45.5%). These findings strongly support the notion that increased PBMC miR-150 levels 
are associated with AMD. This trend held true both above and below median age, making it highly unlikely 
that the differences in PBMC miR-150 levels in AMD patients versus non-AMD controls were solely due 
to the fact that the AMD patients were, on average, older.
Figure 4. Upregulation of microRNA-150 in human peripheral blood mononuclear cells (PBMCs) is associated with age-related macular degeneration 
(AMD). (A) AMD patients (n = 43) had higher PBMC microRNA-150 copy numbers compared with controls (n = 63; 2-tailed Mann-Whitney U test). (B) Both 
early AMD (n = 20) and wet AMD patients (n = 23) had higher PBMC microRNA-150 copy numbers compared with controls (n = 63), but there was no signif-
icant difference between early and wet AMD patients (Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test). (C) There was no correlation 
between PBMC microRNA-150 copy number and age in AMD patients or controls. Patients in the highest tertile of microRNA-150 copy number and above 
median age, as indicated by the dashed rectangle, had the highest prevalence of AMD (87.5%). Open circles depict individual human subjects (A–C); hori-
zontal lines depict medians (A and B) (**P < 0.01; ***P < 0.001; ****P < 0.0001).
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miR-150 directly targets Scd2 and promotes pathologic angiogenesis. To understand the mechanism by which 
miR-150 promotes macrophage dysfunction, we sought to identify direct miR-150 targets. Since miRs 
canonically downregulate their gene targets, we filtered for commonly downregulated genes (fold change 
< –1.2) both in miR-150OE and NC-transfected macrophages and in aged versus young macrophages. This 
strategy identified 36 initial putative target genes (Supplemental Table 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.120157DS1). We further narrowed this list by 
eliminating genes that either did not appear in any of  6 target identification databases or did not contain a 
seed sequence in their 3′ UTR. We performed qPCR in aged versus young macrophages on the remaining 
26 genes. Of  these 26 genes, 8 showed significant downregulation in aged macrophages (Figure 5, A and 
B). Of  interest, 2 of  the 8 genes that were significantly downregulated in aged macrophages are known to 
play key roles in fatty acid biosynthesis: fatty acid synthase (Fasn) and Scd2. We confirmed that both genes 
were indeed downregulated in miR-150OE macrophages versus NC-transfected macrophages (Figure 5, C 
and D). To determine the functional effect of  Fasn and Scd2 deficiency, we performed siRNA knockdown of  
these gene targets in macrophages and assessed the inflammation status and angiogenic potential of  these 
macrophages by PCR array. We confirmed siRNA knockdown of  Fasn and Scd2 by qPCR (Figure 5, E and 
F). Fasn-deficient macrophages exhibited upregulation of  only Ptgs2 and Tnf (Figure 5G) and no upregula-
tion of  proangiogenic factors (Figure 5H). On the other hand, Scd2-deficient macrophages were abnormally 
activated, with upregulation of  numerous proinflammatory markers (Figure 5I) and proangiogenic factors 
(Figure 5J). Of  interest, Vegfa expression was not altered (Figure 5J), suggesting that Scd2-mediated regula-
tion of  macrophage function is independent from VEGF. These results suggest that Scd2 may be an import-
ant direct target of  miR-150, providing a mechanism by which miR-150 regulates macrophage function.
Next, we performed dual-reporter assays to confirm that miR-150 can directly regulate Scd2 expression. 
The Scd2 gene contains 2 canonical miR-150 seed sequence target sites in its 3′ UTR: a 7mer-A1 (3′ - UGG-
GAGA - 5′) and an offset 6mer (3′ - UUGGGA - 5′) (Figure 6A). As expected, cotransfection of  a plasmid 
with the Scd2 3′ UTR cloned downstream of  a secreted Gaussia luciferase (GLuc) and miR-150 mimic led 
to decreased GLuc activity compared with cotransfection of  the same plasmid with a nontargeting mimic 
(Figure 6B). Removing the 7mer-A1 target site (mutant 1) significantly reduced the extent to which miR-
150 cotransfection reduced GLuc activity (Figure 6C). In contrast, removing the offset 6mer target site 
(mutant 2) did not change the negative regulatory effect of  miR-150 cotransfection on GLuc activity (Fig-
ure 6C). These findings suggest that the 7mer-A1 site is the dominant target site to which miR-150 binds to 
regulate Scd2 expression, while the offset 6mer site plays a less important role.
To determine whether downregulation of  Scd2 may promote pathological angiogenesis, as seen in wet 
AMD, we measured the extent to which Scd2-deficient macrophages inhibited choroidal neovascularization 
(CNV) in a well-established murine model of  injury-induced angiogenesis in the eye. Although host macro-
phages play an important role in regulating CNV, we have previously demonstrated that intravitreal injec-
tion of  functional macrophages can augment the antiangiogenic effect (27). Therefore, we performed laser 
injury to induce CNV and injected Scd2-deficient or NC-transfected macrophages intravitreally by adoptive 
transfer immediately after injury. Adoptively transferred Scd2-deficient macrophages were not able to inhib-
it CNV as effectively as NC-transfected macrophages (Figure 6, D and E). This phenomenon was indepen-
dent of  VEGF since VEGF mRNA expression and protein secretion was not increased in Scd2-deficient 
macrophages (Figure 5H and Figure 6F). To confirm these in vivo results, we also generated mice lacking 
Scd2 in myelomonocytic cells, including macrophages, with the Cre-lox system (Scd2–m/–m). In agreement 
Table 2. Age-related macular degeneration as a function of age and peripheral blood mononuclear cell (PBMC) microRNA-150 
(miR-150) levels
Age
Below median Above median Total
PBMC miR-150
Lowest tertile 3/19 (15.8%) 3/16 (18.8%) 6/35 (17.1%)
Middle tertile 4/23 (17.4%) 7/13 (53.8%) 11/36 (30.6%)
Highest tertile 5/11 (45.5%) 21/24 (87.5%) 26/35 (74.3%)
Total 12/53 (22.6%) 31/53 (58.5%) 43/106 (40.6%)
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with our adoptive transfer experiments, Scd2–m/–m mice had larger CNV complexes after laser injury com-
pared with floxed controls (Scd2f/f) (Figure 6, G and H). In contrast, mice lacking Fasn in myelomonocytic 
cells (Fasn–m/–m) and floxed controls (Fasnf/f) had similar CNV complex sizes after laser injury (Figure 6, I 
and J). These findings confirm that Scd2 plays an important role in regulating macrophage function in the 
context of  pathological angiogenesis.
Figure 5. microRNA-150 modulates fatty acid synthase (Fasn) and stearoyl-CoA desaturase-2 (Scd2) expression. (A and B) Eight of the 26 puta-
tive microRNA-150 targets had decreased expression in aged macrophages (n = 6-12/group; 2-tailed, unpaired Welch’s t test). (C and D) microR-
NA-150 mimic–transfected macrophages had reduced expression of Fasn and Scd2 compared with nontargeting negative control-transfected 
(NC-transfected) macrophages (n = 12/group; 2-tailed, unpaired student’s t test). (E and F) Macrophages transfected with Fasn- and Scd2-targeting 
small-interfering RNA (siRNA) had reduced expression of target genes (n = 4-5/group; 2-tailed, unpaired student’s t test; KD, knock down). (G and 
H) Fasn-deficient (FasnKD) macrophages were somewhat abnormally activated but had normal expression of proangiogenic factors (n = 14/group; 
2-tailed, unpaired Welch’s t test). (I and J) Scd2-deficient (Scd2KD) macrophages were abnormally activated and had increased expression of proan-
giogenic factors (n = 10/group; 2-tailed, unpaired Welch’s t test). Open circles depict individual data points; graphs depict mean ± SEM (C–F) (*P < 
0.05; **P < 0.01; ***P < 0.001; #P < 0.0001).
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Figure 6. microRNA-150 directly targets Scd2 and thereby promotes pathological angiogenesis. (A) The 3′ untranslated region (UTR) of Scd2 con-
tains canonical 7mer-A1 and offset 6mer microRNA-150 binding sites. (B) Cotransfection of a dual-reporter plasmid with the Scd2 3′ UTR inserted 
downstream of a secreted Gaussia luciferase (GLuc) reporter gene and microRNA-150 mimic led to reduced GLuc activity compared with cotransfec-
tion of the same plasmid with a negative control (NC) mimic (n = 10/group; 2-tailed, unpaired student’s t test). (C) Removing the 7mer-A1 target site 
(mutant 1) but not the offset 6mer target site (mutant 2) reduced the extent to which microRNA-150 cotransfection inhibited GLuc activity (n = 10/
group; Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test). (D and E) Adoptively transferred Scd2-deficient (Scd2KD) macrophages 
were less able to inhibit laser injury–induced choroidal neovascularization (CNV) compared with NC-transfected macrophages (D, representative 
images from n = 8–11 burns/group; 2-tailed, unpaired Welch’s t test). (F) In vitro VEGF secretion was not significantly increased in Scd2-deficient 
macrophages (n = 16/group; 2-tailed, unpaired Welch’s t test). (G and H) Scd2–m/–m mice exhibited larger CNV complexes after laser injury compared 
with Scd2f/f mice (G, representative images from n = 8–9 burns/group; 2-tailed Mann-Whitney U test). (I and J) Fasn–m/–m and Fasnf/f mice had similarly 
sized CNV complexes after laser injury (I, representative images from n = 8 burns/group; 2-tailed Mann-Whitney U test). Scale bars: 100 μm (D, G, I). 
Open circles depict individual data points; graphs depict mean ± SEM (B, E, F, H, J) (*P < 0.05; ***P < 0.001).
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Together, these findings indicate that Scd2 downregulation secondary to miR-150 upregulation in aged 
macrophages promotes macrophage dysfunction and pathological angiogenesis, providing a mechanism by 
which miR-150 can direct macrophages toward an aged, disease-promoting, and proangiogenic phenotype 
(Figure 7). Our human data confirm the translational relevance of  these findings in AMD pathogenesis.
Discussion
In this study, we report that miR-150 is upregulated in aged murine macrophages of  diverse origins and 
directs aged macrophages toward a disease-promoting phenotype characterized by abnormal activation 
and promotion of  pathologic angiogenesis. miR-150 was previously reported to play important roles in 
controlling B cell differentiation by targeting the transcription factor c-Myb (28). Moreover, miR-150 has 
been reported to regulate de novo lipogenesis by targeting Fasn and other lipid-related genes in mammary 
epithelium (29). Here, we uncover a potentially novel role for miR-150 in macrophages to regulate choles-
terol metabolism and lipid trafficking genes involved in AMD based on our RNA-Seq results. In agreement, 
other miRs have been shown to regulate cholesterol homeostasis. For example, miR-33 (4, 30), miR-302a 
(31), and miR-19b (32) regulate reverse cholesterol transport by modulating Abca1 expression.
Consistent with their impaired cholesterol metabolism and lipid trafficking, we report that aged mac-
rophages with miR-150 upregulation have associated alterations in ceramide and phospholipid profiles. 
These results build on our previous finding that aged macrophages have impaired cholesterol efflux (4). 
Specifically, aged macrophages have a reduced ratio of  very long–chain to long-chain ceramides. Cera-
mides are important signaling molecules in macrophages that modulate cellular responses in many path-
ways, including inflammation (33). Different molecular ceramide species have been shown to be signifi-
cantly associated with mortality in coronary artery disease patients independently of  traditional risk factors 
(34), highlighting their importance in disease pathogenesis. Additionally, we demonstrate that aged mac-
rophages have alterations in phospholipid composition in multiple classes. Of  interest, both ceramides and 
phospholipids are important components of  the plasma membrane, and the composition and organization 
of  the plasma membrane have been shown to be important for modulating cholesterol-dependent signaling 
networks involved in inflammation (26).
We propose that broad disruptions in plasma membrane lipids secondary to miR-150 upregulation in 
aged macrophages modulate the inflammatory status of  aged macrophages and thereby predispose them 
toward a disease-promoting, proangiogenic phenotype. Our lipidomic analysis shows that aged macro-
phages possess a complex profile of  altered lipid composition with remodeling toward long-chain cera-
mides and a shift toward phospholipids containing unsaturated fatty acids. We provide further insight by 
demonstrating that 1 molecular mechanism by which miR-150 regulates lipid metabolism in macrophages 
is direct targeting of  Scd2. This gene catalyzes the rate-limiting step in the formation of  monounsaturated 
Figure 7. Upregulation of miR-150 in aged macrophages causes stearoyl-CoA desaturase-2 deficiency and dysregulated lipid metabolism, thereby pro-
moting pathological angiogenesis, as seen in age-related macular degeneration.
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fatty acids and has been shown to be important in lipid synthesis during early skin and liver development 
(35). Our data establish that Scd2 is also evidently important in macrophage function, as Scd2-deficient mac-
rophages exhibit abnormal activation and promote pathological angiogenesis. Although Scd2 deficiency 
alone might be expected to cause accumulation of  phospholipids containing saturated fatty acids in aged 
macrophages, we did not observe this pattern in our lipidomic analysis, suggesting that Scd2 deficiency does 
not drive alterations in lipid composition alone. We propose instead that the combination of  Scd2 deficien-
cy and changes in other lipid-related genes causes the altered lipid profile of  aged macrophages.
Of  translational relevance, our study provides strong evidence that miR-150 plays a role in AMD 
pathogenesis. Specifically, our data indicate not only that AMD patients have higher PBMC miR-150 levels 
than control participants, but also that increased PBMC miR-150 is significantly associated with increased 
odds of  AMD in a sex- and age-adjusted binary logistic regression model. Although miR-150 levels were 
associated with disease in human PBMCs, there was no clear relationship between miR-150 levels and age, 
unlike in murine macrophages, highlighting a difference between murine and human macrophages.
Overall, our findings are timely, given a recent report that showed that there is an increase in the num-
ber of  choroidal macrophages in human eyes with AMD (36), strongly implicating a pathogenic role for 
macrophages in disease. Moreover, our findings may partially explain why activated macrophages derived 
from neovascular AMD patients have proangiogenic characteristics (37, 38). While other groups have sug-
gested that endothelial miR-150 may suppress pathologic ocular neovascularization (39, 40), our findings 
highlight a distinct, macrophage-specific role for miR-150 that, in fact, promotes pathological ocular neo-
vascularization. These differences are not surprising, given that miRs can act in a cell-specific manner. 
Ultimately, these findings open up therapeutic vistas for miR-based therapies for AMD. Moreover, under-
standing the mechanisms that cause macrophage aging and how such aging contributes to AMD also has 
broad applicability to other age-associated diseases by educating us about critical unifying pathways that 
drive their pathobiology.
Methods
Animals. We obtained 18-month-old, WT C57BL/6J mice from the National Institute on Aging and com-
pared them with strain-matched, young (i.e., 2- to 3-month-old) WT controls. We obtained mice with floxed 
Fasn alleles (Fasnf/f) (41) from Clay Semenkovich (Washington University School of  Medicine) and mice 
with floxed Scd2 alleles (Scd2f/f) (42, 43) from Hide Tsukamoto (Keck School of  Medicine of  the University 
of  Southern California, Los Angeles, California, USA). We crossed these floxed mice with mice carrying 
the lysozyme M-Cre (LysMcre) transgene (44) to generate mice with myelomonocytic-specific deletion of  
Fasn (Fasn–m/–m) and Scd2 (Scd2–m/–m). We harvested PMs, SMs, and BMDMs from female mice at the ages 
indicated and used equal proportions of  male and female mice for laser-injury CNV experiments. Unless 
otherwise specified, we used mice that were 2–3 months of  age for experimentation.
Macrophages. We harvested PMs from mice 5 days after elicitation with 4% thioglycollate (MilliporeSig-
ma). We harvested SMs from mice by mincing spleens with a razor blade, incubating in spleen disso-
ciation medium (Stemcell Technologies) for 30 minutes at room temperature, and performing magnetic 
cell separation with the PE selection kit (Stemcell Technologies) and PE-conjugated F4/80 monoclonal 
antibody (clone BM8; eBioscience), following manufacturer’s instructions. We cultured PMs and SMs in 
RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS (Atlanta Biologicals) and 1% 
penicillin-streptomycin (Thermo Fisher Scientific). Additionally, we generated BMDMs by culturing BM 
aspirates from mice in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 20% L929-con-
ditioned medium, 10% FBS (Atlanta Biologicals), 1% GlutaMAX (Thermo Fisher Scientific), and 1% pen-
icillin-streptomycin (Thermo Fisher Scientific). Monocytes were allowed to differentiate for 1 week prior to 
experimentation. When indicated, we treated macrophages with 25 μg/ml oxLDL (Intracel) for 24 hours, 
25 μg/ml acLDL (Intracel) for 24 hours, or 100 ng/ml LPS (MilliporeSigma) for 24 hours.
miR microarray. We profiled miR expression of young and aged PMs that (i) were left untreated, (ii) were 
treated with 25 μg/ml acLDL for 24 hours, or (iii) were treated with 25 μg/ml oxLDL for 24 hours (total of  
6 groups; 3 treatments × 2 ages). We extracted RNA with the mirVana miRNA isolation kit (Thermo Fisher 
Scientific), determining quantity and quality of the RNA with a 2100 BioAnalyzer and the Total RNA Pico kit 
(Agilent Technologies). All samples (n = 24) had RNA integrity numbers (RIN) > 9.5. We labeled each sample 
with FlashTag Biotin HSR RNA Labeling Kits (Affymetrix) to prepare them for the GeneChip miRNA 3.0 
Array. We processed the array results with Affymetrix Expression Console (v1.3.1.187) at standard settings 
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(RMA background correction, median polish summarization, and quantile normalization) to generate intensi-
ty values with a second set of data produced without quantile normalization. We filtered the data by probeset 
type and by detection call and removed probesets without a “detected” call in any of the 24 samples; after this 
filtering, we retained 1,093 of the initial 1,966 probesets for further statistical analysis. To identify potential 
outliers, we performed principal component analysis (PCA) and hierarchical clustering and assessed quality 
control (QC) metrics from Expression Console (e.g., all probeset RLE means > 0.25). This analysis identified 3 
outliers, which we omitted from further analysis. We performed statistical analysis with the R package “limma” 
(45) to generate lists of miRs differentially expressed in our various groups based on their P values and FDR-ad-
justed P values (i.e., q values). The microarray data are available at the Gene Expression Omnibus (GEO) at 
NCBI under accession number GSE111323.
miR expression profiling. For miR expression profiling, we extracted total RNA with the mirVana miR-
NA isolation kit (Thermo Fisher Scientific) and prepared cDNA with the universal cDNA synthesis kit II 
(Exiqon). We then performed qPCR using ExiLENT SYBR Green master mix (Exiqon) and miR LNA 
primer sets (Exiqon). To analyze the data, we used the ΔΔCT method, normalizing to U6 expression. A list 
of  primers used for miR qPCR is provided in Supplemental Table 2.
mRNA expression profiling. For mRNA expression profiling, we extracted RNA with the RNeasy kit 
(Qiagen) and prepared cDNA with the high-capacity cDNA reverse transcription kit (Thermo Fisher Sci-
entific). We then performed qPCR with TaqMan fast advanced master mix (Thermo Fisher Scientific) and 
TaqMan real-time PCR gene expression assays (Thermo Fisher Scientific). A list of  primers used for qPCR 
is provided in Supplemental Table 2. We also profiled mRNA expression with custom TaqMan array plates 
(Thermo Fisher Scientific) with the assays indicated in Supplemental Table 3. We used the ΔΔCT method, 
normalizing to 1 or more housekeeping gene, as appropriate.
RNA-Seq. We extracted total RNA from PMs transfected with either synthetic miR–150-5p or NC 
(Exiqon) with TRIzol (Thermo Fisher Scientific), followed by column purification with the RNeasy Plus 
mini kit (Qiagen). We determined the quantity and quality of  the RNA samples with a 2100 BioAnalyzer 
and the Total RNA Pico kit (Agilent Technologies). All samples (n = 12) had RIN > 9.6. We analyzed the 
transcriptomes of  PMs after miR-150 overexpression with RNA-Seq, with an initial input of  600 ng of  
total RNA per sample before mRNA enrichment with the rRNA Ribo-Zero rRNA removal kit (Illumina). 
We prepared sequencing libraries with standard protocols. QC revealed improper fragmentation of  1 sam-
ple, which was omitted from further analysis. The remaining samples (n = 11) were sequenced in 2 flow-
cell lanes on a HiSeq 2500 (Illumina) at the Washington University Genome Technology Access Center 
(GTAC). We mapped the sequencing reads to the genome with Spliced Transcripts Alignment to a Refer-
ence (STAR) (https://github.com/alexdobin/STAR). Next, we performed a standard EdgeR and Sailfish 
analysis of  gene-level features. We defined a significant up- or downregulation as a |fold-change| > 1.20 
with a FDR < 0.20. We performed pathway analysis for enrichment in GO processes, process networks, 
and pathway maps with MetaCore (Clarivate Analytics). The RNA-Seq data are available at the GEO at 
NCBI under accession number GSE111323.
Lipidomic analysis. We suspended macrophages in PBS at 2.0 × 106 cells/ml and performed protein 
precipitation from 100 μl of  macrophage suspension to extract ceramides, PCs, PEs, PIs, PGs, and PSs. 
Prior to extraction, we added deuterated d5-Cer (16:0), d4-Cer (22:0), and d4-Cer (24:0) as internal standards 
for ceramides and PC (28:2), PE (32:2), PG (30:0), PI (32:0), and PS (28:0) as internal standards for the 
other lipid classes. We measured lipids with a Shimadzu 10A HPLC system and a Shimadzu SIL-20AC 
HT auto-sampler coupled to a Thermo Scientific TSQ Quantum Ultra triple quadrupole mass spectrometer 
operated in SRM mode under ESI(+). We conducted data processing with Xcalibur (Thermo Fisher Scien-
tific). We prepared QC samples by pooling aliquots of  the study samples and injected them between every 
5 samples to monitor instrument performance, omitting lipid species with coefficients of  variance >15% in 
QC samples. We performed relative quantification by comparing the peak area ratios of  the analytes to the 
corresponding internal standards.
Human subjects. To isolate PBMCs, we performed density gradient centrifugation with BD Vacutainer CPT 
cell preparation tubes. We stored PBMC pellets at –80°C until further analysis. We classified patients as no 
AMD, early AMD, or wet AMD based on established clinical criteria (46). Early AMD patients had either 
moderate drusen (>63 μm) or pigment changes in at least 1 eye but no CNV or GA in either eye at the time of  
sample collection. Wet AMD patients had CNV in at least 1 eye at the time of sample collection. We excluded 
patients with pattern dystrophy, macular telangiectasia, dominant drusen, or central serous chorioretinopathy.
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Absolute miR-150 quantification in human PBMCs. We extracted RNA from PBMCs with the mirVana 
miRNA isolation kit (Thermo Fisher Scientific) and performed reverse transcription (RT) with the univer-
sal cDNA synthesis kit II (Exiqon) by adding 2 μl of  RNA to 2 μl of  5× reaction buffer, 1 μl of  enzyme 
mix, and 5 μl of  nuclease-free H2O (total volume, 10 μl). We diluted the cDNA to a final volume of  60 μl 
and performed miRCURY LNA Universal RT miR PCR by adding 4 μl of  diluted cDNA to 1 μl of  the 
appropriate primer and 5 μl of  ExiLENT SYBR Green master mix (total volume, 10 μl). To determine 
absolute copy number of  human-miR-150-5p (hsa-miR-150-5p), we prepared standard curves with serial 
dilutions of  synthetic hsa-miR-150-5p (Integrated DNA Technologies) ranging from 1 × 104 copies per 2 
μl input to 1 × 1010 copies per 2 μl input, followed by RT and PCR as above. To account for differences 
in RNA extraction and RT efficiency performed on separate occasions, we spiked in 20 fmol of  synthetic 
C. elegans–miR-39-3p (cel-miR-39-3p) (Integrated DNA Technologies) into each sample prior to RNA 
extraction and normalized to the global arithmetic mean. We normalized miR-150 copy number for each 
patient by dividing by the total RNA used for RT.
miR-150 overexpression. To transiently overexpress miR-150 in PMs, we used commercially available 
miRCURY LNA miR mimics (Exiqon), following standard protocols for fast-forward transfection. In 
short, we plated PMs at 1 × 106 cells/well in 6-well plates. Two hours after plating, we prepared transfec-
tion complexes by combining miR mimic (20 nM) and HiPerFect transfection reagent (18 μl/well; Qia-
gen) in RPMI medium supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillin-streptomycin 
(Thermo Fisher Scientific), incubating for 15 minutes at room temperature before adding to the cells. We 
assessed transfection efficiency with fluorescence microscopy by visualizing fluorescein amidite–labeled 
(FAM-labeled) miR mimics.
miR-150 target identification. To identify miR-150 targets, we retrieved 3′ UTR sequences from the UCSC 
Genome Brower (genome.ucsc.edu; Mouse Assembly GRCm38/mm10) and manually searched for the 
presence of  relevant miR-150 seed sequences (8mer site: 3′ - UUGGGAGA - 5′; 7mer-m8 site: 3′ - UUGG-
GAG - 5′; 7mer-A1 site: 3′ - UGGGAGA - 5′; 6mer site: 3′ - UGGGAG - 5′; offset 6mer site: 3′ - UUGG-
GA - 5′). Additionally, we used existing miR target identification databases: TargetScanMouse (release 7.1) 
(47), DIANA-microT-CDS (version 5.0) (48), DIANA-TarBase (version 7.0) (49), miRDB (50), RNA22 
(version 2.0) (51), and microRNA.org (August 2010 release) (52).
Fasn/Scd2 knockdown. To transiently knock down Fasn and Scd2, we used commercially available Flex-
iTube siRNA (Qiagen), following standard protocols for fast-forward transfection. In short, we plated PMs 
at 1 × 106 cells/well in 6-well plates. Two hours after plating, we prepared siRNA transfection complexes 
by combining siRNA (50 nM) and HiPerFect transfection reagent (18 μl/well; Qiagen) in RPMI medium 
supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillin-streptomycin (Thermo Fisher Scientif-
ic), incubating for 15 minutes at room temperature before adding to the cells. We confirmed efficient siRNA 
knockdown by qPCR. We analyzed macrophage activation and function 48 hours after transfection.
miRNA target dual-reporter assays. We ordered custom miTarget 3′ UTR miRNA target clones from 
GeneCopoeia with WT or mutated Scd2 3′ UTR inserted downstream of  a secreted GLuc reporter gene 
driven by the SV40 promoter and a secreted alkaline phosphatase (SEAP) reporter gene driven by a CMV 
promoter. We cotransfected 293T cells (ATCC), cultured routinely in high-glucose DMEM (Thermo Fisher 
Scientific) supplemented with 10% FBS (Atlanta Biologicals), with the target clone and either miR-150 mim-
ic or nontargeting NC mimic (Exiqon), following manufacturer’s instructions. In brief, we plated 293T cells 
in 96-well plates at 2 × 104 cells/well the day before transfection. On the day of  transfection, we prepared 
transfection complexes by combining the target clone (100 ng/well), miR mimic (20 nM), Lipofectamine 
3000 (0.15 μl/well; Thermo Fisher Scientific), and P3000 reagent (0.20 μl/well) in Opti-MEM medium 
(Thermo Fisher Scientific) and incubating for 30 minutes at room temperature before adding to the cells. 
Forty-eight hours after transfection, we collected the supernatant to measure GLuc activity with the Secrete 
Pair Dual Luminescence assay kit (GeneCopoeia). We normalized for transfection efficiency by measuring 
SEAP activity. We optimized cotransfection conditions with a positive-control pmaxGFP plasmid (Lonza).
CNV experiments. We performed laser-induced CNV as described previously (53). Briefly, we anesthetized 
mice and placed 4 laser spots around the optic disc (200 mW, 0.1 second, 100 μm spot size) using a slit-lamp 
delivery system with a cover glass as a contact lens. Seven days after injury, we perfused the mice with 2,000 
μl of 5 mg/ml FITC-dextran (molecular weight, 2,000,000 daltons; MilliporeSigma) through the left ventricle. 
We then enucleated the eyes and fixed them in 2% paraformaldehyde (PFA; Alfa Aesar) for 30 minutes. After 
fixation, we washed the eyes with PBS and flat-mounted the retinal pigment epithelium–choroid (RPE-choroid) 
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complex onto a glass slide. We acquired Z-stack images of the CNV spots using an Olympus FV1000 confocal 
microscope and processed images with ImageJ (NIH) to generate pseudo-volumetric 2-dimensional images. 
After excluding laser spots that resulted in retinal, subretinal, or vitreous hemorrhage, we quantified pixel intensi-
ty using MetaMorph (Molecular Devices). For immunotherapy experiments, we adoptively transferred 100,000 
macrophages into each eye in 2 μl PBS immediately following laser injury via intravitreal injection with a 10 μl 
Neuros Model 1701 RN syringe (point style 4) and small-hub, 31-gauge needles (Hamilton).
VEGF measurements. We measured VEGF secretion in supernatants from macrophages with the mouse 
VEGF Quantikine ELISA kit (R&D Systems), following manufacturer’s instructions.
Statistics. We performed statistical analysis with Prism 5 (Graphpad) or SPSS Statistics (Version 23; 
IBM). We assessed the normality of  our data graphically and with the Kolmogorov-Smirnov test, using 
nonparametric alternatives when appropriate. When comparing a single variable between 2 groups, we used 
2-tailed t tests or 2-tailed Mann-Whitney U tests. For other analyses, we performed the appropriate statistical 
test for each type of  data, as indicated in figure legends. A P value less than 0.05 was considered significant. 
Open circles depict individual data points or individual human subjects. Box-and-whisker plots depict medi-
ans, with boxes outlining the interquartile range and whiskers indicating the minima and maxima.
We performed an a priori power calculation with G*Power 3.1 (54) to determine the appropriate sample 
size for our human studies. To detect a significant difference between AMD patients and control subjects 
(allocation ratio: 1.0:1.5) at the 2-sided α = 0.05 level with an estimated effect size d of  0.6 based on pilot 
experiments and 80% power, we calculated that we needed to recruit 94 subjects total. We exceeded this 
threshold (n = 106), yielding adequate statistical power to detect our anticipated difference. To model the 
relationship between PBMC miR-150 levels and AMD, we generated a binary logistic regression model. 
Our model included the predictor variables of  age at the time of  sample collection, sex, and log10-trans-
formed PBMC miR-150 levels. We assessed model fit with the Hosmer-Lemeshow lack-of-fit test and 
performed model diagnostics by examining Cook’s distances, leverages, and residual deviances. No cases 
were omitted upon sensitivity analysis. We checked for collinearity by examining variance inflation factors 
(VIF). We used an unadjusted α of  0.05 for the binary logistic regression.
Study approval. All animal experiments were reviewed and approved by the IACUC of  Washington 
University in St. Louis and performed in accordance with the Washington University School of  Medicine 
Animal Care and Use guidelines. The human study was reviewed and approved by the Human Research 
Protection Office of  Washington University in St. Louis and adhered to the Declaration of  Helsinki. We 
obtained informed consent from all human subjects prior to blood collection.
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